Our commitment to quality: batch by batch
Avextra offers high-quality cannabis-based medicines. Our strength lies within our cultivation in Portugal and the combination of traditional and high-tech extraction methods in Germany. Discover more insights from our CMO David Reckeweg-Lecompte by watching this video.
A selection of other videos
Compiled from the various subject areas.
We at Avextra have had an exciting and successful year! In 2024, we achieved many important milestones. As we look ahead to the next chapter of our journey in 2025, here is look back at some of our key highlights from 2024.
Reflecting on a remarkable and successful year at Avextra. We’re ready for another year of achievements in 2024.
Avextra combines decades of experience in plant-based pharmaceutical production with innovative manufacturing processes. Our experts harness the therapeutic potential of the cannabis plant to improve patients' quality of life.
Avextra offers high-quality cannabis-based medicines. Our strength lies within our cultivation in Portugal and the combination of traditional and high-tech extraction methods in Germany. Discover more insights from our CMO David Reckeweg-Lecompte by watching this video.
At Avextra, we focus on research and development of cannabis medicine to create innovative dosage forms and drive evidence-based research. Learn more with this video.
Hear from Avextra’s experts how we are setting new standards in cannabis medicine and realizing the full potential of the plant in this video clip.
Check out our state-of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes tour!
Our 2022 highlight video gives a sneak peek at some of the exciting things we've been working on and hints at what's to come.
Europe’s leader in Cannabis-based medicine
Das komplette Interview zu möglichen Vorteilen der Therapie mit medizinischem Cannabis finden Sie im Media Center für Fachkreise.
Das komplette Interview über den Einsatz von Cannabis-Medizin in der Palliativmedizin finden Sie im Media Center für Fachkreise.
Das komplette Interview zum möglichen Einsatz von Cannabis-Medizin in der Kinderpalliativversorgung finden Sie im Media Center für Fachkreise.
Podcasts
Neil Smith featured on Planted with Sara Payan.
Sara discusses the European cannabis landscape and new movement in R&D with Neil Smith, COO of German bio-pharmaceutical company Avextra.
Press Releases
Please find the latest press releases from Avextra here.
Veteran Banker Joins Avextra’s Supervisory Board
Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board,…
Avextra Showcases Study Findings on World Sleep Day 2025
Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association…
Avextra Unveils Promising Study Results at Major Pain Congress
Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra…
Avextra expanding its product portfolio of cannabis-based medicines
Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…
Avextra Portugal stellt sein State-of-the-Art Pflanzengenetik-Programm zur Entwicklung eigener THC- und CBD-Kultivare vor
Lissabon, Portugal, 20. November 2024 — Avextra Portugal stellt sein innovatives internes Pflanzen-Genetikprogramm vor…
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial
Bensheim, Germany, Oct. 08, 2024 — Avextra AG…
Deutsches Start-up Avextra will „Cannabis-Blockbuster“ entwickeln
Das Handelsblatt hat das hessische Cannabis-Biotech-Unternehmen Avextra porträtiert und gibt Einblicke in die Arzneimittelentwicklung Made in Germany.
Avextra und SynQube GmbH geben strategische Partnerschaft in der Arzneimittelentwicklung bekannt
Avextra und SynQube geben ihre strategische Partnerschaft bekannt. Beide Partner bündeln ihre umfangreiche Expertise im Bereich der Cannabistherapie für eine verbesserte Patientenversorgung in der GKV-Erstattung.
Veteran Banker Joins Avextra’s Supervisory Board
Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board,…
Avextra Showcases Study Findings on World Sleep Day 2025
Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association…
Avextra Unveils Promising Study Results at Major Pain Congress
Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra…
Avextra expanding its product portfolio of cannabis-based medicines
Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
Lisbon, Portugal, November 20, 2024 — Avextra Portugal is excited to announce that its innovative in-house breeding program is now operational…
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial
Bensheim, Germany, Oct. 08, 2024 — Avextra AG…
German start-up Avextra wants to develop “cannabis blockbusters”.
The Leading German Business Publication Handelsblatt did a profile on the German cannabis biotech company Avextra providing insights into botanical drug development Made in Germany.
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development
Avextra and SynQube jointly announce their strategic partnership. Both partners are combining their extensive expertise in the field of cannabinoid therapy to improve patient care…
PRESS CONTaCT
